ABCL is the most slept-on biotech binary event of 2026 and you're all too busy buying 0DTE SPY puts to notice

Alright degenerates, put down the weekly options for 5 minutes and hear me out. AbCellera Biologics (ABCL) — Canadian biotech, antibody discovery platform, and the company about to drop a Phase 2 readout that management literally called "by far the most important data readout in 2026." When management says that, you listen. THE PLAY: ABCL-635 is a treatment for postmenopausal vasomotor symptoms (hot flashes). ~$6B U.S. market. Phase 1 already showed: ✅ No liver toxicity (huge, this kills most drugs) ✅ ~24-d